title: Metabolic effect of PGE1 analogue 01206.alpha CD on nerve Na(+)-K(+)-ATPase activity of rats with streptozocin-induced diabetes is mediated via cAMP: possible role of cAMP in diabetic neuropathy.
abstract: We investigated the dose-dependent effects of prostaglandin E1 (PGE1) analogue, OP1206.alpha CD (OP), on motor nerve conduction velocity (MNCV), nerve blood flow (NBF) and Na(+)-K(+)-ATPase (ATPase) activity in streptozocin-induced diabetic rats. At 10 micrograms/kg/day, OP ameliorated MNCV and NBF, but no ATPase activity, whereas at 30 micrograms/kg/day it increased MNCV and ATPase activity, but not NBF. These results suggested a possible direct metabolic effect of OP, at least at a certain dose, on ATPase activity independent of NBF. Since PGE1 exerts an effect on nerve cAMP content, we conducted an in vitro study to clarify the relationship of cAMP to the modulation of ATPase activity in diabetic nerves. We studied sciatic nerves isolated from 53 rats with streptozocin-induced diabetes that had exhibited hyperglycemia for 6 wk. OP increased the activity of ATPase and the accumulation of cAMP in a dose-dependent manner. Dibutyryl cAMP, a cAMP analogue, and aminophyline, which increases nerve cAMP content, enhanced ATPase activity in a dose-dependent manner. In addition, the increased activity of ATPase in diabetic nerves produced by OP was suppressed by a protein kinase inhibitor, H8. These results suggest that ATPase activity in diabetic nerves might be regulated or modified by cAMP and, possibly, by protein kinase A, a finding that is important for clarifying the pathogenesis of diabetic neuropathy and for developing new approaches to treatment.
authors.affiliation: Third Department of Medicine, Shiga University of Medical Science, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Yasuda
authors.forename: K
authors.initials: K
authors.lastname: Maeda
authors.forename: M
authors.initials: M
authors.lastname: Sonobe
authors.forename: T
authors.initials: T
authors.lastname: Kawabata
authors.forename: M
authors.initials: M
authors.lastname: Terada
authors.forename: T
authors.initials: T
authors.lastname: Hisanaga
authors.forename: Y
authors.initials: Y
authors.lastname: Taniguchi
authors.forename: R
authors.initials: R
authors.lastname: Kikkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Shigeta
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000242:Cyclic AMP / Q000502:physiology*; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology / Q000378:metabolism*; D003929:Diabetic Neuropathies / Q000378:metabolism*; D066298:In Vitro Techniques; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000201:enzymology*; D000254:Sodium-Potassium-Exchanging ATPase / Q000187:drug effects* / Q000378:metabolism; D013311:Streptozocin
chemical_list: D013311:Streptozocin; C025090:ONO 1206; D000242:Cyclic AMP; D000254:Sodium-Potassium-Exchanging ATPase; D000527:Alprostadil